You are here: Industry Insights > lung cancer

News List

Takeda's Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use fiercepharma
September 27, 2018
Pfizer’s targeted therapy Xalkori is about to get even more competition in previously untreated ALK-positive lung cancer. And if new data are any indication, it’s pretty stiff.
EU approves AstraZeneca immunotherapy drug for lung cancer expressbpd
September 26, 2018
The green light from the EU had been expected following a positive recommendation from experts at the European Medicines Agency
New AI tool accurately identifies lung cancer type biospectrum
September 20, 2018
A new computer program can analyze images of patients' lung tumors, specify cancer types, and even identify altered genes driving abnormal cell growth, a new study shows.
Merck extends I/O lead as EU Oks Keytruda in first line lung cancer biopharmadive
September 17, 2018
Keytruda (pembrolizumab) continues to dominate in first-line NSCLC approvals, which have fueled its rapid sales growth and transformed Merck into an immunotherapy leader.
EC green-lights MSD’s Keytruda combo for lung cancer September 13, 2018
The European Commission has approved MSD’s Keytruda for use in combination with Eli Lilly’s Alimta and platinum-based chemotherapy for the first-line treatment of some advanced lung cancers.
Keytruda scores ground-breaking European approval in lung cancer subgroup September 13, 2018
Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based chemotherapy in the first-line...
Glythera rebrands as Iksuda, pledging to solve ADC problems fiercebiotech
September 11, 2018
Despite their promise, antibody-drug conjugates (ADCs) have been tricky to bring to market, but the U.K. biotech formerly known as Glythera wants to change that.
Bristol-Myers surprise: Threatened I-O drug Opdivo stands its ground in lung cancer fiercepharma
July 30, 2018
Investors may be worried about Bristol-Myers Squibb’s future in lung cancer, but in the meantime, the company’s portfolio is firing on all cylinders.
AZ’ Tagrisso offers sustained benefit in lung cancer pharmatimes
July 17, 2018
AstraZeneca says that the “unprecedented progression-free survival benefit” of Tagrisso when used as a first line treatment for lung cancer is sustained through subsequent lines of therapy.
Pfizer's Xalkori makes it onto Cancer Drugs Fund pharmatimes
July 12, 2018
NICE has published draft guidance recommending that Pfizer's Xalkori (crizotinib) to treat ROS1-positive advanced non-small-cell lung cancer is made available via the Cancer Drugs Fund (CDF).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page